Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Ireland Strategy Companies

Merck Sharp & Dohme submits Irish plant plans

This article was originally published in Scrip

Executive Summary

Merck Sharp & Dohmesubmitted phase I plans for a new €200 million facility to Carlow County Council, Ireland, this month. The plant, located on a 65-acre site in the IDA Business Park on Dublin Road, Carlow, will create 170 positions once operating and 300 construction jobs whilst being built. MSD general manager Bryan Meehan said Carlow offered strategic location, size and infrastructure. Construction is scheduled to begin in October, with the facility scheduled to be operational in 2011.

Table

View full table

Topics

Tags:
Ireland Strategy Companies
Latest Headlines

Podcast: Facilitating Patient Monitoring in CAR-T Development

Stock Watch: Novartis And The Changing Face Of Big Pharma

Cash-Rich SynOx Well Placed To Compete In Hot TGCT Field

Quick Listen: Scrip's Five Must-Know Things

See All
UsernamePublicRestriction

Register

SC004976

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By